(2S,3S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid

We are (2S,3S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid CAS:201481-37-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: (2S,3S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid
CAS.NO: 201481-37-0
Molecular Formula:C23H27NO5
Molecular Weight: 397.46400

Synonyms:
(2S,3S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(tert-butoxy)butanoic acid
L-Allothreonine, O-(1,1-dimethylethyl)-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-
N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-O-(2-methyl-2-propanyl)-L-allothreonine
Fmoc-Allo-Thr(tBu)-OH

Physical and Chemical Properties:
Density: 1.2±0.1 g/cm3
Boiling point: 581.7±50.0 °C at 760 mmHg
Melting point: /
Flash point: 305.6±30.1 °C
Refractive index: 1.569

Specification:
Appearance: White Crystalline Powder
Purity:≥98%

Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store at 2-8ºC.Keep the container tightly closed, put it in a tight dispenser, and store in a cool, dry place.
Application:pharmaceutical intermediates.

Related News: In order to find answers to these questions, our staff in the development department set about conducting a series of experiments.452-67-5 In addition, due to the complex process of changing the API supplier and the risk of uncertainty, the viscosity of pharmaceutical and specialty API companies is usually better.2-bromo-2-metilpropionato de metilo CAS:23426-63-3 In addition, due to the complex process of changing the API supplier and the risk of uncertainty, the viscosity of pharmaceutical and specialty API companies is usually better.(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethanamine In addition, due to the complex process of changing the API supplier and the risk of uncertainty, the viscosity of pharmaceutical and specialty API companies is usually better.Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037.